ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 493

Trends in the Incidence of SOLID Tumors in Patients with Rheumatoid Arthritis in Spain. a National Observational Cohort Study

Virginia Villaverde García1, Manuel Fernández2, Ramon Mazzucchelli3, Cristina Macia-Villa4, Gloria Candelas5, Javier Quirós3, M Peña3, E Perez-Fernandez3, Natalia Crespí6, Alberto Garcia-Vadillo7, Carmen Barbadillo8, J.L Morell-Hita9, Hilda Godoy8, Maria Espinosa10, C Morado-Quiñoa5, Cristina Martinez-Prada5, María Galindo11, O Guzon-Illescas3 and Angela Herranz12, 1Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain, 2Hospital Universitario de Guadalajara, Guadalajara, Spain, 3H.U.Fundación Alcorcón, Madrid, Spain, 4Hospital Universitario Severo Ochoa, Madrid, Spain, 5H.U. Clínico San Carlos, Madrid, Spain, 6C.S. La Rivota, Madrid, Spain, 7Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 8H.U. Puerta de Hierro, Madrid, Spain, 9H.U.Ramón y Cajal, Madrid, Spain, 10Rheumatology, H.U. Puerta de Hierro, Madrid, Spain, 11Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, 12H.U. del Henares, Madrid, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: During the last 20 years, the treatment in rheumatoid arthritis (RA) has changed. Considering the increasing use of biological immunomodulators to treat chronic inflammatory conditions and the concern that immunomodulation may alter cancer risk and progression, it’s important to know the tumors incidence in patients with RA. The objective of this study was to analyze the incidence and trend of hospital admissions for solid tumors in patients with RA in Spain during the period between 1999 and 2015.

Methods: This is a retrospective population based study. We have analized a national administrative database that includes a Minimum Basic Data Set (MBDS) of hospital admissions of RA patients during the period 1999 to 2015. We selected the MBDS for solid tumors (breast, colon, pancreas, prostate, lung, pleura, melanoma, ovary, cervix, uterus, bladder and kidney). Cases were identified by the presence in primary and secondary diagnosis of ICD 9 codes. The population at risk was estimated through the population census of the National Institute of Statistics, with an estimated prevalence of RA of 0,5% (0,8% in women and 0,2% in men). Crude and adjusted rates of the solid tumors were calculated, and the trend was analyzed using the Generalized Linear Model (GLM) with the year as the analysis variable.

Results:338.343 RA hospital admissions were detected in the study period, being 18.401 (5,4%) due to solid tumors. The main clinical-demographic characteristics are shown in the next table.

 

Total

Women

Men

 P value

N (%)

18.401 (5,4)

8689 (3,8)

9712 (8,6)

P<0,001

Age, mean (SD)

69,98 (11,21)

68,62 (12,3)

71,20 (9,99)

P<0,001

In-hospital exitus n (%)

2455 (13,34)

1035 (11,9)

1420 (14,62)

P<0,001

Charlson Index, mean (SD)

5,72 (2,95)

5,63 (2,95)

5,80 (2,95)

P<0,001

Stay, mean (SD)

10,94 (11,6)

10,76 (11,6)

11,1 (11,77)

P=0,051

The solid tumor adjusted rate during the study period was 647,53/105 inhabitants/yr (366,97/105 in women and 1792,99/105 in men; relative risk men:women =4,8). This rate increased from 305,65/105 in 1999 to 993,19/105 inhabitants/yr in 2015 (814,06/105 in 1999 to 2535,5/105 in 2015 in men and from 181,68/105 in 1999 to 607,71/105 in 2015 in women). The annual age-adjusted rate increased significantly: 7,37% (6,52% in men and 8,02% in women; p≤0,001).

 Figure 1.

Conclusion: There was an increasing incidence of hospital admissions due to solid tumors in RA in Spain during the period 1999-2015. An annual rate increase of 7.37%, is estimated.

 


Disclosure: V. Villaverde García, None; M. Fernández, None; R. Mazzucchelli, None; C. Macia-Villa, None; G. Candelas, None; J. Quirós, None; M. Peña, None; E. Perez-Fernandez, None; N. Crespí, None; A. Garcia-Vadillo, None; C. Barbadillo, None; J. L. Morell-Hita, None; H. Godoy, None; M. Espinosa, None; C. Morado-Quiñoa, None; C. Martinez-Prada, None; M. Galindo, None; O. Guzon-Illescas, None; A. Herranz, None.

To cite this abstract in AMA style:

Villaverde García V, Fernández M, Mazzucchelli R, Macia-Villa C, Candelas G, Quirós J, Peña M, Perez-Fernandez E, Crespí N, Garcia-Vadillo A, Barbadillo C, Morell-Hita JL, Godoy H, Espinosa M, Morado-Quiñoa C, Martinez-Prada C, Galindo M, Guzon-Illescas O, Herranz A. Trends in the Incidence of SOLID Tumors in Patients with Rheumatoid Arthritis in Spain. a National Observational Cohort Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/trends-in-the-incidence-of-solid-tumors-in-patients-with-rheumatoid-arthritis-in-spain-a-national-observational-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-in-the-incidence-of-solid-tumors-in-patients-with-rheumatoid-arthritis-in-spain-a-national-observational-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology